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the CC BY-NC-ND license (http://creaAbstract Management of unresectable urothelial cancer (UC) has been a clinical challenge
for decades. While drug resistance is a key issue, precise understanding of biology of UC metas-
tasis is another challenge for the improvement of treatment outcome of UC patients. Introduc-
tion of the cell biology concepts including epithelial-mesenchymal transition (EMT) and cancer
stemness seems to explain UC metastasis. Molecular genetics based on gene expression
profiling, next generation sequencing, and explosion of non-coding RNA world has opened
the door to intrinsic molecular subtyping of UC. Next steps include, based on the recently
accumulated understanding, the establishment of novel disease models representing UC
metastasis in various experimental platforms, particularly in vivo animal systems. Indeed,
novel knowledge molecular genetics has not been fully linked to the modeling of UC metas-
tasis. Further understanding of bladder carcinogenesis is needed particularly with regard to
cell of origin related to tumor characteristics including driver gene alterations, pathological
differentiations, and metastatic ability. Then we will be able to establish better disease
models, which will consequently lead us to further understanding of biology and eventually
the development of novel therapeutic strategies for UC metastasis.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Bladder cancer is the sixth most common malignancy
excluding non-melanoma skin cancers with an estimation of
330,380 new cases and 123,051 deaths from bladder cancer
worldwide in 2012 [1]. Approximately 95% of bladderto-u.ac.jp.
f Second Military Medical Univers
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sian Journal of Urology. Producti
tivecommons.org/licenses/by-nc-cancers are histologically classified as urothelial carcinoma
(hereafter referred as UC, formerly called transitional cell
carcinoma) with the exception of a particular area where
squamous cell carcinoma due to chronic infection of
Schistosoma hematobiumis more prevalent. Urothelium,
where UC is originated, lines all through the urinary tractity.
on and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
212 T. Kobayashiexcept for distal urethra. Therefore, UC can arise from
renal pelvis, ureter, bladder, and proximal urethra.
As many of other malignancies, bladder UC is a disease
of older individuals. Patients are typically in their fifth or
greater decades of life. The majority of bladder UC occur in
males where there is an approximately 2- to 3-fold greater
incidence compared with females. In the United States,
Caucasians are at highest risk for bladder UC among all
races including African, Asian, and Latin Americans. It is
known that smoking and occupational or endemic expo-
sures to certain chemicals predispose us to UC. The un-
derlying mechanisms that link urothelial carcinogenesis to
the sexual and racial disparities and risk factors including
aging and carcinogens are currently not fully understood.
Treatment and prognosis of UC depend on several key
factors including anatomical site, extent (stage), and his-
tological grade of the disease. Non-muscle-invasive bladder
UC (NMIBC),with the exception of carcinoma in situ (CIS),
can be treated by transurethral resection with excellent
survival outcomes, whereas muscle-invasive bladder UC
(MIBC) and upper urinary tract UC (UTUC) often need radical
cystectomy (RC) or nephroureterectomy (RNU). While these
treatments are usually indicated with a curative intent,
there are currently few curative treatment options for a
metastatic or recurrent UC that has progressed outside of
the urinary tract. MIBC is associated with higher incidence
of distant metastasis compared with NMIBC. Bladder UC
often metastasize to lymph nodes, bone, lung, liver, and
peritoneum [2]. Systemic chemotherapy, the standard
treatment for metastatic UC, can hardly achieve durable
disease control. Therefore, treatment outcome of the pa-
tients with metastatic UC has been very poor with approx-
imately 15% of overall survival rate [3].
Thus, it is apparently important to understand the un-
derlying biology for metastatic progression of UC. Recently
published series of molecular genetics of bladder cancer
provided novel information for intrinsic molecular subtyp-
ing of UC [4e6], which will potentially lead us to the
effective prevention and cure of this currently lethal form
of the disease. This article reviews recent key findings that
have been accumulated in the research field of UC metas-
tasis, barriers that hamper our research progression, and
future perspectives that may potentially overcome them.
2. Cell biology of UC metastasis
2.1. Epithelial-mesenchymal transition (EMT)
Several cellular processes are implicated in metastatic
progression of UC. EMT is referred as a complex process
that reprograms and transmogrifies epithelial cells to
mesenchymal phenotype characterized by loss of cell
adhesion and polarity. Although EMT is a phenomenon that
physiologically observed during development and wound
healing, it has long been implicated in cancer metastasis
and treatment resistance. As essential roles of EMT in
urothelial cancer metastasis was extensively discussed in
an excellent review by McConkey et al. [7] in 2009, this
article focuses on relatively recent findings.
One of the most particular molecular characteristics of
cells undergoing EMT is downregulation of surface CDH-1(cadherin 1, also known as E-cadherin) and EMT is best
characterized by decreased expression of CDH-1 and
increased expression of CDH-2 (N-cadherin). Indeed, aber-
rantly attenuated expression of CDH-1 was reported to be
associated with high progression rate of bladder UC [8,9].
Recently Al-Ahmadie et al. [10] observed truncating so-
matic mutations in the CDH-1 gene in 84% of plasmacytoid
bladder cancers, a highly invasive histological variant of
UC. Knock-out of CDH-1 in bladder UC cells enhanced cell
migration, suggesting that loss of CDH-1 expression is not
just a marker for EMT, but has some central, causal, and
functional significance in tumor invasion and progression.
It is well known that numerous signaling pathways
involving TGFb, integrins, Notch, Wnt, and sonic hedgehog
(SHH) induce EMT [7,11]. Recent studies addressed molec-
ular mechanisms involved in TGFb-induced EMT in UC cells.
Those studies revealed malat-1 [12,13] and EIF5A2 [14]
downstream mediators of TGFb signaling pathway that
induce EMT. Another study showed that PPM1A functions as
a negative regulator of EMT by dephosphorylating TGFb-
activated Smad2/3 [15]. Although those reports suggest
that TGFb signaling promotes EMT in UC, another study
showed that GDF15, a member of TGFb superfamily, in-
hibits EMT through upregulating mammary serine protease
inhibitor (MASPIN) and N-myc downstream-regulated family
genes (NDRG1, NDRG2, and NDRG3) [16]. Additionally, it is
yet to be fully understood what cellular interaction
including auto- and para-crine mechanisms induce TGFb
signaling in the microenvironment of UC tumors.
Several recent reports suggested that integrins and
associated signaling pathways are implicated in EMT of UC.
Integrins mediate cellular adhesion to extracellular matrix
(ECM). In the process of EMT, coordinated regulation of the
integrin-mediated celleECM adhesion and E-cadherin-
mediated cellecell adhesion is required [17]. A report
showed that knockdown of av integrinsled UC cells to a shift
towards more epithelial track characterized by increased
CDH-1/CDH-2 ratio and downregulation of EMT-associated
genes including SNAI2, NANOG, BMI1, ALDH1 [18]. Impor-
tantly, these phenotypic changes were associated with
decreased metastatic growth ability of the cells. Integrin-
linked kinase (ILK) is highly evolutionally conserved serine/
threonine kinase binding to b1 integrin [19]. Like other focal
adhesion molecules such as c-Src and FAK, it mediates
outside-inside signal transduction from ECMeintegrin inter-
action. It was reported that ILK expression is higher in
mesenchymal UC cells compared with epithelial ones [20].
Exogenous expression of ILK led epithelial UC cells to
mesenchymal shift through activation of GSK3beZeb1
pathway. Importantly, ILK expression is positively correlated
with invasive phenotype of human and murine bladder UC.
These findings indicate that ECMeintegrin adhesion plays a
key role for cancer cell plasticity as well as E-cadherin-
mediated cellecell adhesion.
When we consider that EMT occurs physiologically during
embryonic development and tissue repair, it is not sur-
prising that EMT in cancer cells are also regulated by the
developmental signaling pathways including SHH, Wnt, and
Notch pathways. Specifically, recent studies have shed light
on the role of SHH signaling in urothelium and UC. Beachy’s
group found that basal urothelial cells expressing SHH
gave a rise of whole urothelial layer [21]. They also
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tial for the development of CIS, an early form of mesen-
chymal UC [22]. However, they observed that SHH
expression in CIS was lost as it progresses to invasive
bladder UC. Additionally, they reported that inhibition of
SHH dramatically accelerated tumor progression and
decreased survival time [23]. These findings suggest a
tumor-suppressive function of SHH signaling despite
another essential role in the maintenance of epithelial
stem cell or tumor-initiating cells. It is consistent with a
previous report showing more abundant SHH expression in
NMIBC compared with MIBC [24]. However, there have been
a few reports showing positive correlations between SHH
expression and clinicopathological aggressiveness of
bladder UC [25,26]. Accordingly, the role of SHH in UC is
warranted to be elucidated in the future studies as it can be
a potent therapeutic target.
It is well known thatWnt/b-catenin signaling pathway also
regulates EMT in various cancers [27]. b-catenin interacts
with E-cadherin or triggers the activation of EMT-inducing
transcription factors including SNAIL (Snail 1/2/3), TWIST
(Twist 1/2), and ZEB (Zeb 1/2). It was reported that
homeodomain-interacting protein kinase-2 (Hipk2) nega-
tively regulated EMT and subsequent invasion by inhibiting
Wnt/b-catenin signaling pathway in UC cells [28]. Several
other reports also demonstrated that Wnt/b-catenin
pathway activation induced EMT in UC cells [13,29].
Recent studies have shed light on several different as-
pects of the biology of Notch in bladder cancer including
EMT. A report revealed that Notch acted as a tumor sup-
pressor by inhibiting ERK pathway [30]. Another report
showed that disruption of Rbpj and Psen, important medi-
ators of Notch signaling, promoted bladder squamous cell
carcinoma (SCC) with mesenchymal features in N-butyl-N-
(4-hydroxybutyl) nitrosamine (BBN)-induced mouse bladder
carcinogenesis model [31]. Another group, inspired by
genomic gain of Notch2 in The Cancer Genome Atlas
(-TCGA) dataset, has shown that overexpression of Notch2-
intracellular domain (N2ICD) promoted growth and EMT of
UC cells [32]. These findings indicate that Notch1/2/3 have
distinct and context-dependent functions in various aspects
of biological processes in UC. Further understanding is
needed for specific targeting of Notch pathways in the
management of UC patients.
Finally, some carcinogenic chemical substances have
been reported to induce EMT in UC cells. Benzidine is
known as a strong urothelial carcinogen. A previous report
showed that benzidine induced EMT of normal bladder
urothelial cells through activation of ERK1/2 pathway [33].
Chronic exposure to arsenic acid causes UC as well as skin
and lung cancers [34]. It was reported that arsenic acid
induced EMT in lung and prostate epithelial cells [35e37].
However, precise mechanisms of arsenic acid-induced UC
carcinogenesis or progression have not been elucidated.
Aristolochic acid, a compound found in Chinese herbs, is
known to induce progressive tubulointerstitial fibrosis,
chronic renal insufficiency, and upper urinary tract UC [38].
Aristolochic acid was reported to induce EMT in human
proximal tubule epithelial cells [39], while affected uro-
thelial cells frequently undergo T/A transversion in codon
139 of exon 5 of p53 gene [40]. Mechanistic association
between the two observations is not fully understood andsubject to the future studies. These agents have been
implicated in carcinogenesis based on their potential to
induce EMT on normal epithelial cells. As described above
and elsewhere [7], however, EMT is strongly associated with
local invasion and metastatic progression of cancer cells as
well. Indeed, it was reported that bladder cancers associ-
ated with arsenic acid exposure was more aggressive than
those in unexposed patients [41].
2.2. Cancer stem cell or tumor-initiating cell
Several investigators reported that cancer stem cells or
tumor initiating cells of UC were successfully isolated based
on the expression of cell surface markers or some func-
tional molecules [42e45]. In addition to markers commonly
proposed for tumor-initiating cells of solid cancer including
CD24, CD44, CD133, and ALDH1A1, several unique markers
such as CK14 have been identified as UC stem cell markers
[45]. Intriguingly, tumor-initiating cells displayed distinct
marker profiles according to stage and grade of original
tumor, suggesting that phenotype of tumor-initiating cells
defines biological and clinical aggressiveness of bladder UC
[46].
Cancer stem cell hypothesis is an important concept for
the understanding of cancer biology including the multistep
process of tumor metastasis. Provided that cancer stem cell
theory is closely associated with the process of EMT
[45,47,48], it is not surprising that tumor-initiating cells seem
to play an important role in UC metastasis, while it is also
reported to be responsible for chemo-resistance of UC
[45,49]. Indeed, cancer stemness and EMT were mutually
linkedby commonmarkers includingOCT4,NANOG, SNAI1/2,
ZEB1/2 and TWIST [42,45]. Indeed, expressions of various
stem cell markers including OCT4 [50,51], ALDH1A1 [52],
ZEB1/2 [53], and TWIST1 [54] were reported to be associated
with bladder UCmetastasis (extensively reviewed by van der
Horst et al. [45]). However, another study on stem cell
markers and EMT signature questioned the strict correlation
between cancer stemness and EMT in bladder UC cells [55].
Apart from EMT, Overdevest et al. [56] reported that
bladder UC cells expressing stem cell marker CD24 had
higher potential of lung metastasis. CD24-expressing cells
showed higher early retention to the lungs after tail vein
injection, suggesting that CD24 expression promoted lung
colonization. However, another group reported that CD24
expression did not alter tumor-initiating ability in the sub-
cutaneous xenograft model [57].
Importantly, matched pair immunohistochemical anal-
ysis using primary bladder UC and lung metastasis tumors
demonstrated that lung metastatic lesion expressed higher
CD24 compared with corresponding primary tumors. Addi-
tionally, another study showed that CD24 expression was
associated with inferior post-RC survival in bladder UC pa-
tients [57].
CD24 is considered as a luminal marker as it is expressed
in superficial umbrella cells of normal urothelium [57] and
luminal subtypes of UC [5]. It is notable that a luminal
marker is associated with higher metastasis ability and poor
prognosis of cancer. In this regard, these traits of CD24 as a
molecular marker for poor prognosis and luminal subtypes
have been also reported in breast cancer [58], suggesting
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static ability and luminal characteristics. Further studies
are warranted for the elucidation of CD24 function in can-
cer in the future.
2.3. Role of tumor microenvironment
It is obvious that above-mentioned cellular signaling path-
ways (TGFb, integrins, Notch, Wnt, and SHH) regulating
EMT and tumor stemness are closely associate with tumor
microenvironment, which has been increasingly studied in
recent years as exemplified by the Beachy’s reports
showing epithelial-mesenchymal interaction mediated by
SHH and Wnt in urothelial regeneration [21] and UC
development and progression [22,23]. Another report
showed that, in the tumor microenvironment, UC cells and
recruited mast cells cooperatively enhanced EMT and
metastasis by modulating ERb/CCL2/CCR2 signaling
pathway [59]. Another group investigated infiltration of
tumor-associated macrophage (TAM) by assessing CD163
expression [60]. CD163 expression was positively correlated
with local expression of IL-6 and IL-10. Interestingly, CD163
expression was observed not only on TAMs but also on tumor
cells in some cases. Moreover, CD163 expression on tumor
cells was significantly associated with more advanced dis-
ease stage, higher histological grade, and inferior clinical
outcomes. More recently, some investigators focused on
exosome that promotes EMT in an autocrine manner [61].
Indeed, exosomes extracted from some mesenchymal
bladder UC cells contained EMT-related proteins and
reduced expression of CDH-1 and b-catenin in urothelial
cells [62,63].
Like other solid tumors [47,64,65], it is believed that UC
requires tumor-associated stroma to maintain tumor-
initiating cells [43,45,47]. Thus, epithelial-mesenchymal
interaction in tumor microenvironment is increasingly
recognized as important biological processes that are
essential to induce EMT or maintain tumor-initiating cells of
UC. This should be subject to further investigation in the
future studies.
3. Metastasis promoters and suppressors of UC
Recent efforts in UC research identified a number of
metastasis-related genes in UC. Our group identified RalGAP
complex as the GTPase-activating protein (GAP) of small
G-protein Ral [66], which has been implicated in bladder
cancer metastasis and progression [67e69]. Indeed, activity
of Ral in bladder UC cells was inversely correlated with of
RalGAP expression. The expression RalGAP is downregulated
in high grade bladder UC and exogenous expression of Ral-
GAP attenuated cellular metastatic potentials. Additionally,
RalGAPa2 knock-out mice developed more invasive bladder
cancers compared with wild-type animals after administra-
tion of bladder carcinogen BBN [70]. Our results suggested
that RalGAP functions as a tumor metastasis suppressor
through regulating the Ral pathway in bladder UC.
p63, a member of p53 tumor suppressor family, is a basal
cell marker and implicated in maintenance of normal uro-
thelial stem cells. Similar to breast cancer, p63 is categorized
as a basal epithelial marker in UC [5,71]. There are severalisoforms for p63 harboring (Tp63) or lacking (DNp63) N-ter-
minal transactivation domain [72]. It was reported that Tp63
was abundantly expressed in non-invasive bladder UC [73].
Additionally, the same group and others reported that loss of
p63 expression was associated with muscle-invasive pro-
gression or aggressive pathological phenotypes of UC
[72,74e76]. Indeed, a number of reports showed metastasis
suppressor function of p63 in various cancers [77,78]. These
works collectively suggest a tumor metastasis suppressor
function of Tp63 inUC. According to previous reports studying
DNp63 variants specifically, however, a subset of muscle-
invasive bladder cancer expressed DNp63 and maintenance
of DNp63 expression is significantly associated with UC-
specific mortality [72,73]. Collectively, p63 isoforms seem
to have distinct functional significance that is also context-
dependent. Future studies should better dissociate expres-
sion profiles andmolecular function of p63 isoforms at various
biological steps, which would enable us to understand the
role of this interesting molecule for the UC pathogenesis.
Several receptor tyrosine kinases including epithelial
growth factor receptor [79,80], FGFR (fibroblast growth
factor receptor) [81] and c-Met [80,82] have been impli-
cated in UC metastasis (also extensively reviewed by
McConkey et al. [7]). However, it is well known that de-
pendency on FGFR signals is considered as one of the
characteristics of epithelial UC. Consistently, it was re-
ported that mesenchymal UC cells are more likely to show
resistance to an FGFR receptor tyrosine kinase inhibitor
[83]. As for transcription factors, FOXQ1 was reported to
promote EMT of UC cells upon stimulation of TGFb as in
other malignancies [84]. KLF4 was reported to be down-
regulated in UC and act as a metastasis suppressor inhib-
iting EMT [85]. Androgen receptor (AR) was reported to
promote UC metastasis by affecting CD24 [86e88]. Several
investigators reported that infiltrating neutrophils [89] and
B lymphocytes [90] modulated AR transactivation leading to
elevated MMPs expression and cell invasion. Interestingly,
these reports and others [91] showed that AR in UC cells
activated in ligand-independent manners.
c-Src is one of the oldest proto-oncogene that encodes
non-receptor tyrosin kinase. c-Src has been recognized to
promote metastasis of cancers by modifying focal adhesion
and cellecell junction mediated by integrins and cadherins
[92,93]. However, Theodorescu’s group [94] recently re-
ported that c-Src acted as metastasis suppressor in bladder
UC thorough phosphorylating RhoGDI2. Their reports showed
that expression of c-Src was inversely correlated with tumor
stage of bladder UC [94,95]. Considering that a number of Src
inhibitors such as dasatinib have been developed for cancer
treatment, the bilateral roles of c-Src for cancer metastasis
should be further elucidated in the future.
Recently microRNAs (miRNA) have been reported to
regulate various biological processes including tumor inva-
sion and metastasis. To date, miR-200 family (miR-200a,
miR-200b, miR-200c, miR-141 and miR-429) have been most
extensively studied [96e100], while many others such as
miR-205 [101], miR-429 [102], miR-218 [103], miR-23b
[80,104], miR-34a [105], miR-451 [106], miR-145 [107], and
miR-433 [108] have been reported to act as a metastasis
promoter or suppressor. More recent studies have shed light
on long non-coding RNAs (lncRNA) including lncRNA-UCA1
[109], lncRNA-HOTAIR [110], and MALAT-1 [13] as
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were reported to induce EMT through upregulating EMT-
related genes such as ZEB1/2. Accordingly, lncRNAs seem
to be a promising research subject for potential therapeutic
targets and clinically useful urine markers.
4. Therapeutic opportunities
Recent efforts showed some promising findings that
potentially lead us to effective prevention or treatment of
UC metastasis. Several Cox-2 inhibitors was shown to inhibit
UC cell growth as well as reversal of EMT characterized by
induction of CDH-1 and reduction of SNAIL expression [111].
A micro-tubule-targeting agent vinflunine was also reported
to reverse EMT [112]. Vinflunine increased CDH-1 by stabi-
lizing it through inhibiting Hakai, E3-ubiquitin ligase of
CDH-1. Silibinin, a natural flavonoid, was reported to inhibit
GSK3b/b-catenin signaling, decrease ZEB1 expression, and
subsequently suppress metastasis through blocking MET and
stemness of UC cells [113]. A report showed the possibility
that reactivation of p53 through RNA activation using small
activating RNA may inhibit cell growth and EMT of UC cells
[114]. A plant alkaloid tetrandrine was reported to act as
GLI-1 inhibitor blocking Hedgehog signaling and subse-
quently suppress EMT and metastasis of UC cells [115].
Finally, Theodorescu’s group [116] discovered novel small
molecules RBC8 and BQU57 that inhibited Ral activity. They
showed promising effects of these drugs on UC cell growth,
however it is also anticipated that these drugs may also
suppress metastasis of UC since Ral pathways have been
implicated in metastasis of various cancers including UC
[68e70] and others [117e120].
5. Experimental models of UC metastasis
It is essential to have useful models that recapitulate
pathogenesis, biology, and treatment response for theTable 1 Urothelial carcinoma cell lines for metastasis research
Cell line Source Application
253Ja MIBC Orthotopic intramural
Orthotopic intravesica
Caudal vein injection
J82 MIBC Intraperitoneal injecti
Subcutaneous injectio
Caudal vein injection
UM-UC-3a Met. Subcutaneous injectio
Caudal vein injection
Orthotopic intramural
UM-UC-14 MIBC Orthotopic intramural
T24 MIBC Caudal vein injection
TSU-Pr1a,b MIBC Orthotopic intramural
Intracardiac (left vent
Intratibial injection (m
EJ MIBC Caudal vein injection
LN, lymph node; MIBC, muscle-invasive bladder carcinoma; Met., me
a Including derivative sublines.
b Derivative of T24 [154].development of novel treatments of human disease.
Currently a variety of experimental systems are available
for the research on UC metastasis.
5.1. Cell culture experimental systems
A panel of UC cell lines is currently available with the in-
formation for their origin and genetic profile [121]. Cell
culture-based experiments related to metastasis research
include wound healing (“scratch”) assay, Boyden chamber
transwell assays. Wound healing assay is an easy, well-
developed and inexpensive method that has been
employed for years to study cell motility [122]. Boyden
chamber transwell assay utilizes chemotaxis and leads cells
to go across a polycarbonate membrane with micropores
(3e15 mm in diameter). If the membrane is coated with ECM
such as matrigel or collagens, one can see the cellular po-
tential to invade across basement membrane. Transwell
assays with different ECM substances may provide informa-
tion for key molecules that facilitate invasion such as matrix
metalloproteinases (MMPs) [123]. They are useful assays to
dissociate intrinsic cellular motility or migratory potential.
Indeed, abilities of migration and invasion are not neces-
sarily parallel [124]. Additionally, higher motility or inva-
siveness in these assays does not always mean high
metastatic potential of the cells in vivo.
5.2. Cell line-based in vivo experimental systems
(Table 1)
Various approaches currently available to model bladder
cancer in vivo are mostly utilizing mouse [125]. Cell-based
xenograft models are widely used with their potential ad-
vantages. Preparation of the cells is easy including genetic
manipulation for functional assays or reporter expression
for in vivo imaging. However, it inevitably requires immu-
nocompromised animals. Experimental systems based ones.
injection model (LN met.) [137] (Liver met.) [130]
l injection model (LN and lung mets.) [135,136]
model (lung met.) [130]
on model (intraperitoneal spread) [153]
n model (liver met.) [128]
model (liver and lung mets.) [128]
n model (lung met.) [129]
model (lung met.) [56,95,132]
injection model (liver and lung mets.) [82]
injection model (LN mets.) [138]
model (lung met.) [131]
injection model (lung met.) [134]
ricle) injection (lung, liver, brain, LN, bone mets.) [133,134]
imicking tumor growth at bone metastatic lesion) [134]
model (lung met.) [114]
tastatic bladder carcinoma.
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role of immune systems in UC metastasis. Additionally, the
results from these systems should be carefully interpreted
provided the known importance of the immune system for
cancer metastasis [126]. Use of syngeneic system with
mouse bladder cancer cells established from carcinogen-
induced tumors seems to be a good solution in the future.
Subcutaneous injection model is one of the most widely
used cell-based xenograft experimental systems. It is
technically simple and allows easy access to the tumor.
Renal subcapsular engraftment was also reported [127]. It
seems to yield higher take rate due to more abundant blood
flow but requires more sophisticated experimental skills.
Although there are numerous previous reports studying
tumor growth at engraftment site, there are the limited
number of studies that addressed metastatic ability of the
UC cells using these ectopic engraftment models [128,129].
Direct injection of tumor cells into circulation is more
widely used for metastasis researches. In the intravenous
injection, caudal vein injection in most cases, tumor cells
enter the right ventricular (pulmonary) circulatory system
and subsequently form lung metastasis
[56,70,95,114,128,130e132]. On the other hand, in the left
ventricular intracardiac injection, tumor cells enter the left
ventricular (systemic) circulatory system and subsequently
metastasize to bone, liver and brain [133,134]. These
experimental systems allow us to focus biological behavior of
the tumor cells after intravasation into the circulation.
Orthotopic engraft models can be stratified into intra-
vesical injection (instillation into bladder lumen) [135,136]
and intramural injection (inoculation into bladder wall)
[82,130,137,138]. The former primarily mimics the seeding
implantation of superficial bladder cancer and the latter
submucosal progression of infiltrating bladder cancer. Both
methods can be used to investigate metastasis once after
successful tumor engraftment and progression. These
models have an advantage of representing tumor microen-
vironment at the primary site and reflecting multistep met-
astatic process more faithfully. However, the rate of
metastasis formation are usually much lower compared with
intravascular injection models. The primary tumor at the
engraftment site often grows rapidly and the host animal has
to be sacrificed before the development of metastatic le-
sions [139]. Additionally, the intramural inoculation used to
require bladder exposure via lower abdominal incision and
very sophisticated skills for precise injection. A recent
report has shown a modification with less invasive and more
precise procedure using ultrasonography scan [140].
5.3. Patient-derived tumor graft
Patient-derived xenograft (PDX) is a classical experimental
system that has been revisited and growingly become
important [141,142]. Almost all PDX lines are subcutane-
ously engrafted and passaged. This seems to be the main
reason for no prior report on the application of PDX lines for
metastasis researches although only one previous report
showed highly invasive characteristics of the xenograft
[143]. In this regard, orthotopic engraftment of PDX tumor
or dissociated tumor cells seems to be a resolution although
it will be technically challenging.5.4. Chemical-induced bladder cancer
Although a number of chemical carcinogens are known to
induce bladder cancer in rodents, BBN is currently most
widely used for bladder cancer research. Mice administered
with BBN in the drinking water develop CIS and then muscle
invasive bladder cancer eventually. A problem is the model
is high prevalence of squamous cell carcinoma [144,145],
which accounts for less than 10% of human invasive bladder
cancer [146]. Only a few studies reported the metastatic
progression in this model [86,144]. BBN-induced bladder
carcinogenesis model has a potential to be combined with
genetically engineered mice and can be used for functional
association of metastasis-related genes. Additionally, syn-
geneic bladder tumors developed in immunocompetent
animals are suitable for immune-oncological investigations
that are becoming increasingly crucial for the era [147].
5.5. Genetically-engineered mouse (GEM)
As well as the BBN-induced model, GEM models can
represent de novo carcinogenesis in immunocompetent
hosts. Therefore, given relevant genetic alterations in the
right population of the urothelial cells, GEM may recapit-
ulate the pathogenesis and tumor microenvironment of
human disease more faithfully. However, bladder cancer is
still underrepresented by GEM models compared with other
types of malignancies although there are an increasing
number of GEM models of bladder cancer being reported
[125]. Most models develop non-muscle-invasive disease
and metastatic progression is rare even in invasive bladder
cancer models with a few exceptions.
One of these exceptions is SV40T-based transgenic
mouse models. Wu’s group [148] first established a GEM
model harboring Simian Virus 40 T antigen (SV40T) trans-
gene driven by uroplakin II promoter. Although mice hav-
ing low copy number of SV40T transgenes developed only
CIS, those having high copy number developed invasive UC
and some of them showed metastatic progression to lymph
nodes and liver. Another group reported a similar GEM
model based on SV40T transgene driven by cytokeratin 19
(Krt19) promoter [149]. This model was characterized by
lung metastasis that was observed in 25% of the mice.
Unfortunately, non-specific activation of Krt19 led the
mice to develop tumor lesions in other organs including
adrenal glands, prostate and mesothelium. In these GEM
models, however, metastasis is observed in a subset of
affected mice and other investigators reported that they
found no metastasis in similar models [150,151]. These
findings suggest that these gene alterations are not suffi-
cient and that the accumulation of other mutations or
tumor suppressor inactivation are required metastatic
progression.
Another problem in using SV40T-based model is the low
relevancy of the gene alteration that drives mouse bladder
carcinogenesis and progression. The role of SV40T in human
UC is very limited, although inactivation of p53 and Rb,
major targets of SV40T, is among the most frequently
observed genetic events in human MIBC [4] and molecular
profiles of SV40T-based mouse bladder cancers were re-
ported to be conserved with those of human disease [151].
Understanding the biology of urothelial cancer metastasis 217Another GEM model for MIBC metastasis is based on
inactivation of Trp53 and Pten in urothelium [127]. This
model is characterized by stochastic gene recombination in
urothelium induced by Adeno virus expressing Cre recom-
binase that is directly injected into bladder lumen. It was
reported that about 60% of affected mice developed
macroscopically visible metastatic spread. Metastatic loci
were observed most frequently in regional lymph nodes,
while distant metastatic lesions were detected in spleen,
liver, and diaphragm.
However, UC metastasis has not been studied extensively
using these autochthonous mouse models. There seem to be
several aspects of difficulties that hamper UC metastasis
research using autochthonous mouse models. A primary
tumor often becomes lethal causing obstructive renal
insufficiency before the tumor cells metastasize to distant
organs. Bladder tumor of 1 cm in diameter can kill the host
mouse, while a tumor of that size is hardly identified with
concomitant distant metastasis. Higher induction rate
(whatever chemical exposure or gene recombination) or
rapid growth can be an advantage for studies on primary
tumor, but those characteristics may sometimes make
metastasis research difficult. In this regard, use of lentivirus
that usually yields lower infection efficiency compared with
that of Adeno virusmay benefit as succeeded in a lung cancer
research [152]. Another issue is that anatomies of human and
mouse urinary tracts are not exactly same, with particular
regard to blood supply and lymphatic drainage. Mouse
bladder is not enveloped with fat tissue and not insulated
from peritoneal cavity by dense peritoneum like human
bladder. While recent efforts have provided relatively
detailed information about bladder cancer genetics
[4,6,42,71], molecular correlation between subtypes of
human UC and GEM models are still under investigation.
Since the cell of origin for MIBC is still inconclusive [22,145],
there are still limited options to induce gene alterations
specifically to the urothelium. We need to overcome these
barriers in order to establishmore relevant and efficient GEM
models for UC metastasis research in the future.
6. Future directions
The biology of UC metastasis is not fully understood. The
lack of experimental models that accurately recapitulate
the human disease has been one of the main barriers that
has precluded our precise understanding of UC metastasis.
Although several concepts in cell biology such as EMT or
cancer stem cell appear to be attractive to explain biology
of UC metastasis, it does not seem to be fully linked to
in vivo findings in animal models. There is an urgent need
for the establishment of novel animal models that reca-
pitulate molecular, genetic, and clinical characteristics of
human disease. It is anticipated that precise modeling of
the disease will lead us to more profound understanding
and consequently the development of novel therapeutic
strategy to overcome metastasis of UC.Conflicts of interest
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